# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0001021408-25-004365
**Filing Date:** 2025-8
**Character Count:** 7182
**Document Hash:** 6fc6491523a3c512b31c98ba4a8c17a7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001021408-25-004365.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001021408-25-004365

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-25078
- **FILM NUMBER:** 251277059

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0000882095

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Gilead Sciences, Inc.

**Address:** 333 Lakeside Drive, Foster City, CA 94404

**Telephone number:** 650-574-3000

**Name of agent for service:** Andrew D. Dickinson

**Agent Address:** 333 Lakeside Drive, Foster City, CA 94404

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-25078

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER              | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                     | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Allogene Therapeutics, Inc. | 019770106 | 06/18/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                   | SECTION 14A SAY-ON-PAY VOTES |        1156689 |                0 | FOR         |                                  1156689 | FOR                         |  |
| Leap Therapeutics, Inc.     | 52187K200 | 06/18/2025     | To consider and act upon, by a non-binding advisory vote, a resolution to approve the compensation of our named executive officers                                                                   | SECTION 14A SAY-ON-PAY VOTES |        5319148 |                0 | FOR         |                                  5319148 | FOR                         |  |
| Merus N.V.                  | N5749R100 | 05/21/2025     | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.                                                                                          | SECTION 14A SAY-ON-PAY VOTES |         452547 |                0 | FOR         |                                   452547 | FOR                         |  |
| Tango Therapeutics, Inc.    | 87583X109 | 06/05/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |        4854443 |                0 | FOR         |                                  4854443 | FOR                         |  |
| Tango Therapeutics, Inc.    | 87583X109 | 06/05/2025     | Non-binding, advisory vote on the frequency of future non-binding, advisory votes on the compensation of our named executive officers.                                                               | SECTION 14A SAY-ON-PAY VOTES |        4854443 |                0 | 1 YEAR      |                                  4854443 | FOR                         |  |
| Assembly Biosciences, Inc.  | 045396207 | 06/05/2025     | Approval, on a non-binding advisory basis, of our named executive officers' compensation.                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        2209471 |                0 | FOR         |                                  2209471 | FOR                         |  |
| Arcus Biosciences, Inc.     | 03969F109 | 06/10/2025     | To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.                                                              | SECTION 14A SAY-ON-PAY VOTES |       31424760 |                0 | FOR         |                                 31424760 | FOR                         |  |
| Arcellx, Inc.               | 03940C100 | 05/28/2025     | To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement. | SECTION 14A SAY-ON-PAY VOTES |        6720803 |                0 | FOR         |                                  6720803 | FOR                         |  |
| Leap Therapeutics, Inc.     | 52187K200 | 07/02/2024     | Advisory vote on executive compensation paid to named executive officers ("Say-on-Pay Proposal").                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |        5319148 |                0 | FOR         |                                  5319148 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Gilead Sciences, Inc.

**By (Signature):** Andrew D. Dickinson

**By (Printed Signature):** Andrew D. Dickinson

**By (Title):** Executive Vice President and Chief Financial Officer

**Date:** 08/26/2025